RATIONALE: A number of cancer chemotherapeutic agents have been associated with a loss of memory in breast cancer patients although little is known of the causality of this effect. OBJECTIVES: To assess the potential cognitive effects of repeated exposure to chemotherapeutic agents, we administered the selective estrogen receptor modulator tamoxifen or the antimetabolite chemotherapy, methotrexate, and 5-fluorouracil, alone and in combination to mice and tested them in a learning and memory assay. METHODS: Swiss-Webster male mice were injected with saline, 32 mg/kg tamoxifen, 3.2 or 32 mg/kg methotrexate, 75 mg/kg 5-fluorouracil, 3.2 or 32 mg/kg methotrexate in combination with 75 mg/kg 5-fluorouracil once per week for 3 weeks. On days 23 and 24, mice were tested for acquisition and retention of a nose-poke response in a learning procedure called autoshaping. In addition, the acute effects of tamoxifen were assessed in additional mice in a similar procedure. RESULTS: The chemotherapeutic agents alone and in combination reduced body weight relative to saline treatment over the course of 4 weeks. Repeated treatment with tamoxifen produced both acquisition and retention effects relative to the saline-treated group although acute tamoxifen was without effect except at a behaviorally toxic dose. Repeated treatment with methotrexate in combination with 5-fluorouracil produced effects on retention, but the magnitude of these changes depended on the methotrexate dose. CONCLUSIONS: These data demonstrate that repeated administration of tamoxifen or certain combination of methotrexate and 5-fluorouracil may produce deficits in the acquisition or retention of learned responses which suggest potential strategies for prevention or remediation might be considered in vulnerable patient populations.
RATIONALE: A number of cancer chemotherapeutic agents have been associated with a loss of memory in breast cancerpatients although little is known of the causality of this effect. OBJECTIVES: To assess the potential cognitive effects of repeated exposure to chemotherapeutic agents, we administered the selective estrogen receptor modulator tamoxifen or the antimetabolite chemotherapy, methotrexate, and 5-fluorouracil, alone and in combination to mice and tested them in a learning and memory assay. METHODS: Swiss-Webster male mice were injected with saline, 32 mg/kg tamoxifen, 3.2 or 32 mg/kg methotrexate, 75 mg/kg 5-fluorouracil, 3.2 or 32 mg/kg methotrexate in combination with 75 mg/kg 5-fluorouracil once per week for 3 weeks. On days 23 and 24, mice were tested for acquisition and retention of a nose-poke response in a learning procedure called autoshaping. In addition, the acute effects of tamoxifen were assessed in additional mice in a similar procedure. RESULTS: The chemotherapeutic agents alone and in combination reduced body weight relative to saline treatment over the course of 4 weeks. Repeated treatment with tamoxifen produced both acquisition and retention effects relative to the saline-treated group although acute tamoxifen was without effect except at a behaviorally toxic dose. Repeated treatment with methotrexate in combination with 5-fluorouracil produced effects on retention, but the magnitude of these changes depended on the methotrexate dose. CONCLUSIONS: These data demonstrate that repeated administration of tamoxifen or certain combination of methotrexate and 5-fluorouracil may produce deficits in the acquisition or retention of learned responses which suggest potential strategies for prevention or remediation might be considered in vulnerable patient populations.
Authors: Tim A Ahles; Andrew J Saykin; Charlotte T Furstenberg; Bernard Cole; Leila A Mott; Karen Skalla; Marie B Whedon; Sarah Bivens; Tara Mitchell; E Robert Greenberg; Peter M Silberfarb Journal: J Clin Oncol Date: 2002-01-15 Impact factor: 44.544
Authors: Steven A Castellon; Patricia A Ganz; Julienne E Bower; Laura Petersen; Laura Abraham; Gail A Greendale Journal: J Clin Exp Neuropsychol Date: 2004-10 Impact factor: 2.475
Authors: Catherine M Bender; Susan M Sereika; Adam M Brufsky; Christopher M Ryan; Victor G Vogel; Priya Rastogi; Susan M Cohen; Frances E Casillo; Sarah L Berga Journal: Menopause Date: 2007 Nov-Dec Impact factor: 2.953
Authors: Miguel López; Christopher J Lelliott; Sulay Tovar; Wendy Kimber; Rosalía Gallego; Sam Virtue; Margaret Blount; Maria J Vázquez; Nick Finer; Trevor J Powles; Stephen O'Rahilly; Asish K Saha; Carlos Diéguez; Antonio J Vidal-Puig Journal: Diabetes Date: 2006-05 Impact factor: 9.461
Authors: Richard D Ronca; Alyssa M Myers; Doina Ganea; Ronald F Tuma; Ellen A Walker; Sara Jane Ward Journal: Life Sci Date: 2015-05-30 Impact factor: 5.037
Authors: Andrew M Novick; Anthony T Scott; C Neill Epperson; Christopher D Schneck Journal: Front Neuroendocrinol Date: 2020-08-18 Impact factor: 8.606
Authors: Danielle Panoz-Brown; Lawrence M Carey; Alexandra E Smith; Meredith Gentry; Christina M Sluka; Hannah E Corbin; Jie-En Wu; Andrea G Hohmann; Jonathon D Crystal Journal: Neurobiol Learn Mem Date: 2017-08-12 Impact factor: 2.877
Authors: Gisele Pereira Dias; Ronan Hollywood; Mário Cesar do Nascimento Bevilaqua; Anna Claudia Domingos da Silveira da Luz; Robert Hindges; Antonio Egidio Nardi; Sandrine Thuret Journal: Neuro Oncol Date: 2014-01-26 Impact factor: 12.300